PA
CTIC

Perceptive Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Perceptive Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-735,165
Closed -$4.28M – 127
2022
Q3 		$4.28M Buy
+735,165
New +$4.58M 0.12% 86
2014
Q1 		– Sell
-371,500
Closed -$7.13M – 164
2013
Q4 		$7.13M Sell
371,500
-327,967
-47% -$5.97M 0.86% 29
2013
Q3 		$11.3M Buy
+699,467
New +$8.1M 0.92% 27

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Perceptive Advisors's CTIC Position: Q4 2022 in Review

Perceptive Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2022, closing a stake of 735,165 shares — an estimated $4.28M sold.

Perceptive Advisors first reported a position in CTIC in Q3 2013 and held it in 3 quarters. The position peaked at $11.3M in Q3 2013. 145 funds tracked by Wall St. Rank hold CTIC as of Q4 2022.

  • Perceptive Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2022 after selling out during the quarter.
  • Perceptive Advisors sold 735,165 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2022, an estimated $4.28M.
  • Perceptive Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2013 and held it in 3 quarters.
  • Perceptive Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $11.3M in Q3 2013.
  • 145 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2022.

Based on Perceptive Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.